Multiferroic effect of multilayer low-distorted doped bismuth ferrite thin films as a function of sputtering power and crystallographic texture

G. Rojas-George,A. Concha-Balderrama,H. Esparza-Ponce,J.J. Gervacio-Arciniega,M.P. Cruz,V. Orozco-Carmona,A. Reyes-Rojas 한국물리학회 2017 Current Applied Physics Vol.17 No.6

Low-distortion rhombohedral multilayer barium-nickel co-doped BiFeO3 (Bi0.75Ba0.25Fe0.975Ni0.025O3) multiferroic thin films were grown on Pt/TiO2/SiO2/Si substrates by reactive RF magnetron sputtering, as a function of sputtering power. X-ray diffraction showed that Bi0.75Ba0.25Fe0.975Ni0.025O3 multilayer films have a pseudocubic-type structure. Piezoresponse force microscopy demonstrated polarization switching in all films at room temperature. Scanning electron microscopy showed different morphologies depending on the sputtering power used during the deposition process and that the thickness of the film decreases from about 142 nm to 72 nm as the sputtering power decreases. Magnetization results showed that as the thickness of the film decreases, the magnetization of the film increases. Thus, there is a direct relation between the sputtering power, thickness and the magnetization of the film. A direct relation between in-plane residual stress and thin film thickness has been obtained. This causes the main axe of the BO6 octahedra to be tilted from 90 to 45 (from thin-film surface) by a texture crystal volume of 29 and 18% in the (012) and (110) crystallographic planes respectively.

Anti-inflammatory, antioxidant and anti-acetylcholinesterase activities of Bouvardia ternifolia: potential implications in Alzheimer’s disease

Giovanni Garcı ´a-Morales,Arturo Aguilar-Rojas,Maira Huerta-Reye,Manase ´s Gonza ´lez-Cortazar,Alejandro Zamilpa,Enrique Jime ´nez-Ferrer,Rau ´l Silva-Garcı ´a,Rube ´n Roma ´n-Ramos 대한약학회 2015 Archives of Pharmacal Research Vol.38 No.7

Bouvardia ternifolia has been used medicinally to treat inflammation. In the present study, we investigate the anti-Alzheimer’s potential effect of the hydroalcoholic extract of B. ternifolia through evaluation of anti-inflammatory and antioxidant activities, quantification of the percentage inhibition of acetylcholinesterase activity, protection effect against b-amyloid fibrillar-induce neurotoxicity, and the identification of the main constituents. Our results show that B. ternifolia extract and ethyl acetate fraction induced anti-inflammatory effects by reducing inflammation by [70 %, while antioxidant test revealed significant IC50 values for flavonoid content fraction (30.67 ± 2.09 lg/ml) and ethyl acetate fraction (42.66 ± 0.93 lg/ml). The maximum inhibition of acetylcholinesterase was exhibited by scopoletin content fraction (38.43 ± 3.94 %), while ethyl acetate fraction exerted neuroprotective effect against b-amyloid peptide (83.97 ± 5.03 %). Phytochemical analysis, showed the presence of 3-O-quercetin glucopyranoside (415 mg/g), rutin (229.9 mg/g), ursolic and oleanolic acid (54 and 20.8 mg/g respectively), 3-O-quercetin rhamnopyranoside (12.8 mg/g), chlorogenic acid (9.5 mg/g), and scopoletin (1.38 mg/g). Our findings support the use of B. ternifolia since the extract induced significant neuroprotection against b-amyloid peptide, anti-inflammatory, antioxidant and antiacetylcholinesterase effects that could be attributed to its contents of polyphenols, coumarins, and triterpenes, and encourage further studies for development of this extract as therapeutic agent in treatment of Alzheimer’s disease.

Comparative study of the efficacy and safety of Abexol (suspension versus tablets) in patients with gastrointestinal symptoms

Alfredo Hierro González,Julio César Fernández Travieso,Yoandy Hernández Casas,Susana Borges González,María de los Angeles Camacho Morales,Elena Ferrer Batallie,Anaisa Roja Carralera,Yenney Reyes Nuñez 대한내과학회 2024 The Korean Journal of Internal Medicine Vol.39 No.1

Background/Aims: Abexol is a mixture of primary aliphatic alcohols purified from beeswax (Apis mellifera), that produces anti-inflammatory, antioxidant and gastroprotective effects, as well as it is safe and well tolerated. To investigate and compare the efficacy and safety of Abexol (suspension versus tablets) in patients with gastrointestinal symptoms. Methods: Monocentric study, open-label, randomized design, with two parallel groups receiving Abexol tablets (150 mg/d) or Abexol suspension (75 mg/d) for 8 weeks. Primary efficacy variable (significant improvement in the total score of Gastrointestinal Symptom Rating Scale [GSRS]). Significant reduction in the intensity of the gastrointestinal-symptoms and the reduction in the consumption of antacids are considered secondary efficacy variable. Short form-36 (SF-36) quality of life questiongenonaire was evaluated as collateral variable. Data were analyzed as per intention to treat. Results: A significantly decrease in the overall score of the survey was observed with respect to the baseline level (p < 0.001) of 81.4% in the Abexol suspension group and 77.9% in the Abexol tablets group. At the end of the trial, most gastrointestinal- symptoms disappeared or reduced significantly. The frequency of consumption of neutralizing antacids was low. The significantly improvement in the perception of the state of health obtained in the Abexol is in correspondence with the improvement achieved in some of the components evaluate in the SF-36 questionnaire. Both treatments were safe and well tolerated. Conclusions: Abexol suspension showed efficacy and safety similar to Abexol tablets in patients with gastrointestinal symptoms, but using half the dose.

MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia

Mabel Lardo,Marcelo Castro,Beatriz Moiraghi,Francisca Rojas,Natalia Borda,Jorge A Rey,Alberto Lazarowski 대한혈액학회 2015 Blood Research Vol.50 No.3

BackgroundTyrosine kinase inhibitors (TKIs) are the recommended treatment for patients with chronic myeloid leukemia (CML). The MDR1/ABCB1 gene plays a role in resistance to a wide spec-trum of drugs, including TKIs. However, the association of MDR1/ABCB1 gene poly-morphisms (SNPs) such as C1236T, G2677T/A, and C3435T with the clinical therapeutic evolution of CML has been poorly studied. We investigated these gene polymorphisms in CML-patients treated with imatinib, nilotinib and/or dasatinib.MethodsABCB1-SNPs were studied in 22 CML-patients in the chronic phase (CP) and 2 CML-pa-tients in blast crisis (BC), all of whom were treated with TKIs, and compared with 25 healthy controls using nested-PCR and sequencing techniques.ResultsSeventeen different haplotypes were identified: 7 only in controls, 6 only in CML-patients, and the remaining 4 in both groups. The distribution ratios of homozygous TT-variants present on each exon between controls and CML-patients were 2.9 for exon 12, and 0.32 for the other 2 exons. Heterozygous T-variants were observed in all controls (100%) and 75% of CML-patients. Wt-haplotype (CC-GG-CC) was observed in 6 CML-patients (25%). In this wt-group, two were treated with nilotinib and reached a major molecular response. The remaining 4 cases had either a minimal or null molecular response, or developed bone marrow aplasia.ConclusionOur results suggest that SNPs of the MDR1/ABCB1 gene could help to characterize the prognosis and the clinical-therapeutic evolution of CML-patients treated with TKIs. Wt-haplotype could be associated with a higher risk of developing CML, and a worse clin-ical-therapeutic evolution.

MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia

Mabel Lardo,Marcelo Castro,Beatriz Moiraghi,Francisca Rojas,Natalia Borda,Jorge A Rey,Alberto Lazarowski 대한혈액학회 2015 Blood Research Vol.50 No.3

BackgroundTyrosine kinase inhibitors (TKIs) are the recommended treatment for patients with chronic myeloid leukemia (CML). The MDR1/ABCB1 gene plays a role in resistance to a wide spec-trum of drugs, including TKIs. However, the association of MDR1/ABCB1 gene poly-morphisms (SNPs) such as C1236T, G2677T/A, and C3435T with the clinical therapeutic evolution of CML has been poorly studied. We investigated these gene polymorphisms in CML-patients treated with imatinib, nilotinib and/or dasatinib.MethodsABCB1-SNPs were studied in 22 CML-patients in the chronic phase (CP) and 2 CML-pa-tients in blast crisis (BC), all of whom were treated with TKIs, and compared with 25 healthy controls using nested-PCR and sequencing techniques.ResultsSeventeen different haplotypes were identified: 7 only in controls, 6 only in CML-patients, and the remaining 4 in both groups. The distribution ratios of homozygous TT-variants present on each exon between controls and CML-patients were 2.9 for exon 12, and 0.32 for the other 2 exons. Heterozygous T-variants were observed in all controls (100%) and 75% of CML-patients. Wt-haplotype (CC-GG-CC) was observed in 6 CML-patients (25%). In this wt-group, two were treated with nilotinib and reached a major molecular response. The remaining 4 cases had either a minimal or null molecular response, or developed bone marrow aplasia.ConclusionOur results suggest that SNPs of the MDR1/ABCB1 gene could help to characterize the prognosis and the clinical-therapeutic evolution of CML-patients treated with TKIs. Wt-haplotype could be associated with a higher risk of developing CML, and a worse clin-ical-therapeutic evolution.

Flow Diverter Treatment for Non-Ruptured Carotid Aneurysms: Efficacy and Safety

López-Callejas Orlando,Ortiz-Giraldo Andres F,Vera Daniela D,Ramirez-Rojas Diego A,Villamizar-Barahona Ana B,Ferreira-Prada Carlos A.,Galvis Melquizidel,Vargas-Pérez Oliverio,Serrano-Gómez Sergio,Reye 대한신경중재치료의학회 2023 Neurointervention Vol.18 No.1

Purpose: Internal carotid artery (ICA) aneurysm treatment with a flow diverter (FD) has shown an adequate efficacy and safety profile, presenting high complete occlusion or near occlusion rates with low complications during follow-up. The purpose of this study was to evaluate the efficacy and safety of FD treatment in non-ruptured internal carotid aneurysms.Materials and Methods: This is a retrospective, single-center, observational study evaluating patients diagnosed with unruptured ICA aneurysms treated with an FD between January 1, 2014, and January 1, 2020. We analyzed an anonymized database. The primary effectiveness endpoint was complete occlusion (O’Kelly–Marotta D, OKM-D) of the target aneurysm through 1-year follow-up. The safety endpoint was the evaluation of modified Rankin Scale (mRS) 90 days after treatment, considering a favorable outcome an mRS 0-2.Results: A total of 106 patients were treated with an FD, 91.5% were women; the mean follow- up was 427.2±144.8 days. Technical success was achieved in 105 cases (99.1%). All patients included had 1-year follow-up digital subtraction angiography control; 78 patients (73.6%) completed the primary efficacy endpoint by achieving total occlusion (OKM-D). Giant aneurysms had a higher risk of not achieving complete occlusion (risk ratio, 3.07; 95% confidence interval, 1.70 - 5.54]). The safety endpoint of mRS 0-2 at 90 days was accomplished in 103 patients (97.2%).Conclusion: Treatment of unruptured ICA aneurysms with an FD showed high 1-year total occlusion results, with very low morbidity and mortality complications.